International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-6 doi: 10.5281/zenodo.10261847
Original Article
Comparison of Premedication with pregabalin and Gabapentinon Post-Operative Analgesia Inlaparoscopic Cholecystectomy Undergeneral Anaesthesia
 ,
 ,
 ,
Published
Dec. 4, 2023
Abstract

To compare the efficacy of tablet pregabalin (150 mg) and tablet gabapentin (600 mg) on post operative analgesia in elective laproscopic cholecystectomy under general anesthesia. Also secondarily compare the shoulder pain intensity, need for rescue analgesia and compare hemodynamic changes. It can be observed from the present study that the two groups were comparable for age, sex, weight and ASA status of the patients. It was observed that post-operative mean VAS score was significantly different at 4 hr (p value 0.002) and at 8 Hr (p value <0.001) when compared between the two groups. No significant difference in mean VAS score was observed for other time points.  It was concluded that pain score was significantly more in Group G at 4 hr and significantly lower at 8 hrs when compared to Group P.

It was observed that under group P, 88% of the patients had no shoulder pain while 12% had shoulder pain. Under group G, 78% of the patients had no shoulder pain while 22% had shoulder pain (p value 0.183)

It was observed that under group P, rescue analgesic was used in 12% & 88% of the patients after 4 hrs and 8 hrs respectively. Under group G. rescue analgesic was used in 34% & 66% of the patients after 4 hrs and 8 hrs, respectively. (p value <0.001)

Thus it was concluded from our study that pregabalin 150mg and gabapentine 600mg both are suitable and safer alternative for post operative pain management. However pregabalin provides better post operative analgesia

Recommended Articles
Loading Image...
Volume-4, Issue-6
Citations
2220 Views
152 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved